SCYNEXIS Names Marco Taglietti, M.D., Chief Executive Officer
Yves Ribeill, Ph.D., to Remain President, Serve on Board of Directors
Carole Sable, M.D., Submits Resignation as Chief Medical Officer
RESEARCH TRIANGLE PARK, N.C., Feb. 6, 2015 (GLOBE NEWSWIRE) -- Drug discovery and development company SCYNEXIS, Inc. (Nasdaq:SCYX) announced today that its Board of Directors has appointed Marco Taglietti, M.D., as the Company's Chief Executive Officer, effective April 1, 2015. Dr. Taglietti, a member of the SCYNEXIS Board of Directors, will succeed Yves Ribeill, Ph.D. Dr. Ribeill will remain the Company's President and will continue to serve on the SCYNEXIS Board of Directors. In an unrelated matter, Carole Sable, M.D., the Company's current Chief Medical Officer, is stepping down effective February 20, 2015.
"Yves provided remarkable leadership over the last 15 years, building a strong drug discovery organization and successfully ushering SCY-078 into clinical development," said Pamela J. Kirby, Ph.D., Chairman of the Board of SCYNEXIS. "Yves will remain a key member of the management team as we transition Marco's role at SCYNEXIS to Chief Executive Officer. Marco brings to the position an outstanding background and relevant experience in drug development, having led more than 35 drugs and devices through clinical development and onto the market, including several anti-infective products."
"SCYNEXIS is a company with great people, products and potential and I am honored and excited by taking over the role of CEO," said Marco Taglietti, M.D. "SCY-078 has tremendous potential to play an important role in the treatment of life-threatening fungal infections. I look forward to advancing the drug's clinical development as a potential new treatment option to those patients who currently experience high morbidity and mortality."
Dr. Taglietti was appointed to the SCYNEXIS Board of Directors in December 2014. He previously served as Executive Vice President, Research and Development and Chief Medical Officer of Forest Laboratories, Inc. and also as President of the Forest Research Institute until the company was acquired by Actavis, plc. Prior to joining Forest Labs, Dr. Taglietti was Senior Vice President, Head of Global Research and Development at Stiefel Laboratories, Inc. and held various positions with Schering-Plough Corporation where he served as Vice President, Worldwide Clinical Research for Anti-infectives, Oncology, CNS, Endocrinology and Dermatology. He received his medical degree and his Board Certification in Infectious Diseases from the University of Pavia in Italy.
"I have tremendous faith in Marco's ability to lead SCYNEXIS into the future and look forward to working closely with him as we continue to advance the development of our lead compound for the treatment of invasive fungal infections," said Yves Ribeill. "I also want to thank Carole for her work in getting SCY-078 back into the clinic and wish her the best in her next endeavor."
SCYNEXIS is a pharmaceutical company committed to the discovery, development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. We are developing our lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of serious and life-threatening invasive fungal infections in humans. For more information, visit www.scynexis.com.
Forward Looking Statement
Statements contained in this press release regarding matters that are expected to occur in the future are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Risks are described more fully in SCYNEXIS's filings with the Securities and Exchange Commission, including without limitation its most recent Quarterly Report on Form 10-Q and other documents subsequently filed with or furnished to the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. SCYNEXIS undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
CONTACT: Investor Relations Jillian Connell The Trout Group LLC Tel: 646.378.2956 Email: firstname.lastname@example.org Media Relations Heather Savelle MacDougall Biomedical Communications Tel: 781.235.3060 email@example.com SCYNEXIS, Inc. Contact Chuck Osborne Chief Financial Officer Tel: 919.544.8600 firstname.lastname@example.orgSource: SCYNEXIS, Inc.
Released February 6, 2015